Bionity.COM Newsletter No. 22/2010, 06/09/2010

New Products and Services

> more

In- und on-line Particle Size Analysis in Suspensions and Emulsions of high concentrations
Ultrasonic extinction from 0.01 - 3000µm
For many years OPUS is successfully established in crystallization, grinding or homogenization processes and impressively proves its performance. Not for production plants only but also in pilot plants or lab-application OPUS is setting new standards...

http://www.bionity.com/products/e/67008/

Request information

The New Omega Microplate Readers with UV/Vis spectrometer
Another Level of Flexibility
BMG LABTECH announces the new Omega series of multifunction microplate readers with high resolution, full UV/Vis spectrometer based absorbance. This new line of readers combines all of the speed, sensitivity and flexibility needed for life science applications and research...

http://www.bionity.com/products/e/78166/

Request information

How To Efficiently Pre-Concentrate Protein Solutions
For laboratories looking to pre-concentrate protein solutions prior to separation (size exclusion chromatography, electrophoresis) or analysis (x-ray crystallography) the miVac sample concentrator from Genevac provides a highly efficient, cost effective alternative to...

http://www.bionity.com/products/e/116162/

Request information

Universal GC Detector: Detection down to low ppb!
The VICI Pulsed Discharge Detector (PDD) is a universal, non-destructive, high sensitivity helium photoionization detector (HID/PID). The response to both inorganic and organic compounds is linear over a wide range. Response to fixed gases is positive (increase in standing current), with a minimum detectable quantity (MDQ) in the low ppb range...

http://www.bionity.com/products/e/87045/

Request information

Biotech News

> more

Latest News from Biotechnology and Pharma from 06/02/2010 to 06/08/2010

VIB-UGent scientist Jirí Friml receives Körber European Science Award 2010 for research on plant hormones and development
06/08/2010 - Scientist Jirí Friml from VIB and Ghent University, both in Flanders, Belgium, is this year’s laureate of the Körber European Science Award, worth 750 000 euro. The Körber Foundation annually awards E...
http://www.bionity.com/news/e/118681/

Epistem's Biomarker Division Gains GCLP Accreditation
06/08/2010 - Epistem plc has announced that their Biomarker Division has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Biomarker Division conducts gene expression analysis to supp...
http://www.bionity.com/news/e/118605/

Genmab Presents Data from a Pivotal Trial of Zalutumumab in Patients with Refractory Head and Neck Cancer
06/08/2010 - Genmab A/S announced that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients is presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. T...
http://www.bionity.com/news/e/118690/

Zealand Pharma Announces An Extension of The Lixisenatide Global Licensing Agreement with sanofi-aventis for Type-2 Diabetes
06/08/2010 - Zealand Pharma A/S announced that the global licensing agreement with sanofi-aventis has been amended to provide for the development and commercialization of Lixisenatide (AVE0010/ZP10) in combination...
http://www.bionity.com/news/e/118687/

Pieris AG Appoints Chief Scientific Officer
06/08/2010 - Pieris AG announced that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., b...
http://www.bionity.com/news/e/118679/

New treatment regimen shown effective against advanced ovarian cancer
06/07/2010 - Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance do...
http://www.bionity.com/news/e/118600/

Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting
06/07/2010 - Sanofi-aventis reported new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study resu...
http://www.bionity.com/news/e/118601/

YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
06/07/2010 - YM BioSciences Inc. announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and ha...
http://www.bionity.com/news/e/118568/

Selenium shows no benefit in prevention of lung cancer
06/07/2010 - Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer...
http://www.bionity.com/news/e/118599/

CellCept reaches positive results in Phase III trial in Lupus Nephritis
06/07/2010 - Vifor Pharma, the pharma business sector of the Galenica Group, and Roche announced that the maintenance phase of the Aspreva Lupus Management Study (ALMS) has successfully achieved its primary endpoi...
http://www.bionity.com/news/e/118572/

ERBI unveils new name and brand identity: One Nucleus
06/04/2010 - ERBI, the not-for-profit membership company for international life science and healthcare businesses, unveiled its new name and brand identity – One Nucleus – at the opening of its 12th annual Confere...
http://www.bionity.com/news/e/118511/

PregLem announces positivie phase III results from Esmya
PEARL I trial meets primary efficacy and safety endpoints
06/04/2010 - PregLem announced positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma).
The final ...
http://www.bionity.com/news/e/118537/

Raptor Pharmaceutical Licenses Intellectual Property Related to Huntington's Disease
06/04/2010 - Raptor Pharmaceutical Corp. announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann...
http://www.bionity.com/news/e/118510/

Action Pharma completes EUR 5 million financing round to advance its lead project AP214
06/04/2010 - Action Pharma A/S has completed an internal financing round of EUR 5 million which is dedicated to advance the Company’s ongoing phase 2a studies, and the initiation of a phase 2b study, for AP214. ...
http://www.bionity.com/news/e/118514/

EPEMED, the European Personalised Medicine Association, Appoints Executive Director
06/04/2010 - EPEMED has announced the appointment of Dr. Anne Bruinvels, an entrepreneur in personalised healthcare, as Executive Director and board member. Dr. Bruinvels will be responsible for growing the start-...
http://www.bionity.com/news/e/118513/

Jumping Genes Provide Extensive "Raw Material” for Evolution, Penn Study Finds
06/03/2010 - Using high-throughput sequencing to map the locations of a common type of jumping gene within a person’s entire genome, researchers at the University of Pennsylvania School of Medicine found extensive...
http://www.bionity.com/news/e/118501/

Nabriva initiates Phase II of pleuromutilin antibiotic BC-3781
First patient enrolled in Phase II study of BC-3781 in patients with acute bacterial skin and skin structure infections (ABSSSI)
06/03/2010 - Nabriva Therapeutics announced that the first patients have been enrolled in a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections. BC-3781 is a pleuromutilin ant...
http://www.bionity.com/news/e/118505/

immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer
06/03/2010 - immatics biotechnologies GmbH announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical...
http://www.bionity.com/news/e/118508/

Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
Orville Kolterman, MD Named Senior Vice President, Chief Medical Officer
06/03/2010 - Amylin Pharmaceuticals, Inc. announced that Christian Weyer, MD has been appointed Senior Vice President, Research and Development. Orville Kolterman, MD, has been named Senior Vice President, Chief ...
http://www.bionity.com/news/e/118456/

UF oncologists fight leukemia with two-pronged therapy, clinical trials to start within months
06/03/2010 - A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report. Li...
http://www.bionity.com/news/e/118499/

Generex Awarded Two New Patents for its Proprietary Buccal Drug Delivery System
06/02/2010 - Generex Biotechnology Corporation announced that it has been awarded two new patents in Japan and Ukraine.
The Commissioner of the Japan Patent Office granted the Company a patent titled ”Mixed Mic...
http://www.bionity.com/news/e/118443/

Scientists develop new method to identify glycosylated proteins
06/02/2010 - Various processes in our body are controlled by subsequent changes of proteins. Therefore, the identification of such modifications is essential for the further exploration of our organism. Now, scien...
http://www.bionity.com/news/e/118417/

Chakra Biotech Sdn Bhd Changes Its Name to Cerca Insights Sdn Bhd
06/02/2010 - Chakra Biotech Sdn Bhd announced its name change to Cerca Insights Sdn Bhd. The name change follows the recent completion of a Series B investment round with Malaysian Life Sciences Capital Fund Ltd (...
http://www.bionity.com/news/e/118368/

Ubichem Approved for cGMP Radiolabelled API Production
06/02/2010 - Ubichem through its Hungarian operation - Ubichem Research - has successfully completed a regulatory inspection and is now approved for the supply of cGMP radiolabelled Active Pharmaceutical Ingredien...
http://www.bionity.com/news/e/118364/

Kuros completes patient recruitment in a phase IIb trial of KUR-113 in patients with tibial shaft fractures
06/02/2010 - Kuros Biosurgery AG announced that it has completed recruitment in a 200 patient Phase IIb clinical trial designed to assess the efficacy and safety of KUR-113 (Viz.I-040202) in open tibial shaft frac...
http://www.bionity.com/news/e/118441/

Catalogues and Brochures

> more

New Chromatography Products Catalogue!
Tosoh Bioscience features the company's liquid chromatography product lines - the silica and polymer based, porous and non porous TSK-GEL columns as well as the Toyoscreen resin screening columns and the Toyopearl and TSK-GEL resins...

http://www.bionity.com/catalogs/e/101649/

Order catalogue

Organics Handbook
featuring over 40,000 Acros Organics and Maybridge products
It offers a comprehensive portfolio of essential chemicals, functional reagents, and organic building blocks to meet the evolving needs of organic and medicinal chemists in the fields of research and development and drug discovery. Our heritage of quality, packaging innovation and new product development has made us the brands scientists trust for their organics and fine chemicals needs...

http://www.bionity.com/catalogs/e/117327/

Order catalogue

Carl Roth, your competent partner in chemistry, life science and laboratory equipment
The new Carl Roth general catalogue
On its 1,620 pages, the current Carl Roth catalogue contains everything that a lab needs for its daily routine. Thanks to our direct shipment practice you can rely on receiving your goods quickly, usually on the next working day....

http://www.bionity.com/catalogs/e/113147/

Order catalogue

Events

> more

Events, Workshops and Training Courses